Blogger

PoWeR Lectures

HIV and HPV- How to Prevent Anal Cancer? https://www.youtube.com/watch?v=uA2ChPKEsAU HIV Lipodystrophy Update https://www.youtube.com/watch?v=gLML6TiCf4Q&feature=related Bone Health and HIV- https://www.youtube.com/watch?v=QNItQe4-Yjo&feature=related Testosterone Replacement for Men- https://www.youtube.com/watch?v=zO7YLPXRvzs

PoWeR Lectures Read More »

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options

By Nelson Vergel, B.S.Ch.E., M.B.A. July 6, 2011 In a previous blog post, I reviewed the current situation for the minority of patients with HIV who have run out of treatment options. Of the HIV medications in development with potential activity against highly resistant HIV (i.e., patients with GSS=0), two may become available within the next

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options Read More »

Must-See Lecture by Dr Paula Cannon on HIV Cure Research

I am happy to announce that the lecture given by Dr Paula Cannon in Houston sponsored by the Center for AIDS has been uploaded (6 parts since youtube has upload limits) I highly recommend watching this great lecture that explains the current status and future challenges in this important field.  Dr Cannon, a charming speaker, was able

Must-See Lecture by Dr Paula Cannon on HIV Cure Research Read More »

AIDS Nelson Vergel, AIDS expert, talks HIV and healthy aging by Kate Sosin, Windy City Times

https://bit.ly/lRCGbu AIDS Nelson Vergel, AIDS expert, talks HIV and healthy agingby Kate Sosin, Windy City Times2011-06-08 Nelson Vergel and Jeff Berry from TPAN. Photo by Kate Sosin Nelson Vergel is not what you think of when you say “AIDS over 50.”With hefty round muscles pushing out against a tight blue t-shirt and a lively demeanor,

AIDS Nelson Vergel, AIDS expert, talks HIV and healthy aging by Kate Sosin, Windy City Times Read More »

GSK- ViiV start their phase 3 study for their second generation integrase inhibitor (dolutegravir) in raltegravir experienced patients

https://clinicaltrials.gov/ct2/show/NCT01328041?term=dolutegravir&rank=1 For more on dolutegravir: Report from CROI 2011 Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort

GSK- ViiV start their phase 3 study for their second generation integrase inhibitor (dolutegravir) in raltegravir experienced patients Read More »

Nelson’s lecture in Chicago addresses aging with HIV

COH talk addresses aging and HIV/AIDS by MATT SIMONETTE on Jun 5, 2011 • 10:05 am0 Comments and 0 Reactions CHICAGO – A long-time AIDS activist and author spoke May 31 at Center on Halsted, 3656 N. Halsted, about recent breakthroughs in research and potential issues persons with HIV/AIDS might face as they get older. Matt Simonette Long-time AIDS activist

Nelson’s lecture in Chicago addresses aging with HIV Read More »